Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of “Buy” by Brokerages

Alumis Inc. (NASDAQ:ALMS) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $26.83.

Several equities analysts have recently weighed in on ALMS shares. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Alumis in a report on Monday, January 6th. Robert W. Baird assumed coverage on Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Finally, Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $6.68 on Friday. The business has a 50-day moving average of $8.33 and a 200-day moving average of $10.56. Alumis has a fifty-two week low of $6.40 and a fifty-two week high of $13.53.

Institutional Investors Weigh In On Alumis

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC acquired a new stake in Alumis during the third quarter worth approximately $3,266,000. State Street Corp acquired a new stake in Alumis during the third quarter worth approximately $866,000. Charles Schwab Investment Management Inc. acquired a new stake in Alumis during the third quarter worth approximately $1,160,000. Towerview LLC lifted its position in Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after acquiring an additional 70,000 shares during the last quarter. Finally, Stifel Financial Corp acquired a new stake in Alumis during the third quarter worth approximately $931,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.